AstraZeneca invests billions in China for weight-loss drug partnership

AstraZeneca has announced a major $15 billion investment in China through 2030 to strengthen its operations there. As part of this push, the company struck a separate $4.7 billion deal with China's CSPC Pharmaceuticals to boost its pipeline of weight-loss drugs. The moves represent a significant doubling down on the Chinese market.